Recent developments in the treatment of heart failure: Highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3-7 December 2012

Expert Opinion on Investigational Drugs

Volumn 22, Issue 7, 2013, Pages 933-937

  Von Haehling, Stephan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Heart failure; Muscle wasting; Serelaxin; Therapy

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; LOOP DIURETIC AGENT; PLACEBO; RELAXIN; SERELAXIN;

ACUTE HEART FAILURE; ALGORITHM; ARTICLE; ATRIOVENTRICULAR BLOCK; AUTOMATIC DEFIBRILLATOR IMPLANTATION; BODY COMPOSITION; CACHEXIA; CARDIAC CACHEXIA; CARDIAC RESYNCHRONIZATION THERAPY; CARDIORENAL SYNDROME; DEATH; DYSPNEA; EATING HABIT; FEEDING BEHAVIOR; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART PACING; HEART RATE; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTATION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MEDICAL SOCIETY; MUSCLE ATROPHY; SHOCK; SHORT TERM SURVIVAL; SINUS NODE; TREATMENT OUTCOME; ULTRAFILTRATION; UNITED STATES;

CACHEXIA; CARDIAC PACING, ARTIFICIAL; CARDIO-RENAL SYNDROME; CLINICAL TRIALS AS TOPIC; HEART FAILURE; HUMANS; RECOMBINANT PROTEINS; RELAXIN; TREATMENT OUTCOME; ULTRAFILTRATION; WASTING SYNDROME;

EID: 84879074796     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.798301     Document Type: Article

References (20)

1. Hisaw FL. Experimental relaxation of the pubic ligament of the guinea pig. Proc Soc Exp Biol Med 1926;23:661-3
2. Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol 2012;8:293-300
3. Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7:75-82
4. Du XJ, Bathgate RA, Samuel CS, et al. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010;7:48-58
5. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009;373:1429-39
6. Teerlink JR, Cotter G, Davison BA, RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAXAHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39
7. Metra M, Cotter G, Davison BA, RELAX-AHF Investigators. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013;61:196-206
8. Bart BA, Goldsmith SR, Lee KL, Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-304
9. Costanzo MR, Guglin ME, Saltzberg MT, UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83
10. Moss AJ, Schuger C, Beck CA, MADIT-RIT Trial Investigators. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med 2012;367:2275-83
11. Curtis AB, Adamson PB, Chung E, et al. Biventricular versus right ventricular pacing in patients with AV block (BLOCK HF): clinical study design and rationale. J Cardiovasc Electrophysiol 2007;18:965-71
12. Evans WJ, Morley JE, Argilés J, et al. Cachexia: a new definition. Clin Nutr 2008;27:793-9
13. Coats AJ. Research on cachexia, sarcopenia and skeletal muscle in cardiology. J Cachexia Sarcopenia Muscle 2012;3:219-23
14. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997;349:1050-3
15. Fülster S, Tacke M, Sandek A, et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur Heart J 2013;34:512-19
16. von Haehling S, Morley JE, Anker SD. From muscle wasting to sarcopenia and myopenia: update 2012. J Cachexia Sarcopenia Muscle 2012;3:213-17
17. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012;3:77-94
18. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010;1:9-21
19. Gielen S, Sandri M, Kozarez I, et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study. Circulation 2012;125:2716-27
20. von Haehling S. The muscle in dire straits: mechanisms of wasting in heart failure. Circulation 2012;125:2686-8